All In Biotech

Drug Trial Radar · NCT00420212

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jan 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,234 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,234

Actual

Start

Jan 2007

Primary completion

Feb 2011

Study completion Feb 2011

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Jan 11, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse. The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

  • BG00012Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects RelapsedTime frame: 2 years

Locations

159 sites in 29 countries. Site status is shown where the registry gives one.

  • Research Site

    Gilbert, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    San Francisco, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Vero Beach, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Evanston, Illinois

  • Research Site

    Palos Heights, Illinois

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Des Moines, Iowa

  • Research Site

    Wichita, Kansas

  • Research Site

    Lexington, Kentucky

  • Research Site

    Brighton, Massachusetts

  • Research Site

    Hopedale, Massachusetts

  • Research Site

    Lexington, Massachusetts

  • Research Site

    Springfield, Massachusetts

  • Research Site

    Worcester, Massachusetts

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Columbia, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Henderson, Nevada

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Lebanon, New Hampshire

  • Research Site

    Albany, New York

  • Research Site

    Staten Island, New York

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Dayton, Ohio

  • Research Site

    Erie, Pennsylvania

  • Research Site

    Hershey, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    East Providence, Rhode Island

  • Research Site

    Providence, Rhode Island

  • Research Site

    San Antonio, Texas

  • Research Site

    Newport News, Virginia

  • Research Site

    Wien, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Fitzroy, Australia

Showing 40 of 159 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.